WO2019113375A3 - Régimes posologiques pour la mobilisation de cellules souches et progénitrices hématopoïétiques - Google Patents

Régimes posologiques pour la mobilisation de cellules souches et progénitrices hématopoïétiques Download PDF

Info

Publication number
WO2019113375A3
WO2019113375A3 PCT/US2018/064335 US2018064335W WO2019113375A3 WO 2019113375 A3 WO2019113375 A3 WO 2019113375A3 US 2018064335 W US2018064335 W US 2018064335W WO 2019113375 A3 WO2019113375 A3 WO 2019113375A3
Authority
WO
WIPO (PCT)
Prior art keywords
progenitor cells
hematopoietic stem
mobilization
cells
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/064335
Other languages
English (en)
Other versions
WO2019113375A2 (fr
Inventor
Dwight Morrow
Patrick C. Falahee
Anthony Boitano
Michael P. Cooke
Kevin A. GONCALVES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dianthus Therapeutics Inc
Original Assignee
Magenta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/834,017 external-priority patent/US10058573B1/en
Priority to IL315735A priority Critical patent/IL315735A/en
Priority to JP2020531468A priority patent/JP2021505172A/ja
Priority to SG11202004913TA priority patent/SG11202004913TA/en
Priority to EP18829615.6A priority patent/EP3720494A2/fr
Priority to AU2018378804A priority patent/AU2018378804B2/en
Priority to CA3083783A priority patent/CA3083783A1/fr
Priority to IL275077A priority patent/IL275077B2/en
Priority to CN201880088815.6A priority patent/CN111712262A/zh
Application filed by Magenta Therapeutics Inc filed Critical Magenta Therapeutics Inc
Priority to MX2020005878A priority patent/MX2020005878A/es
Priority to BR112020011186-4A priority patent/BR112020011186A2/pt
Priority to KR1020207019222A priority patent/KR20200096942A/ko
Priority to EA202091092A priority patent/EA202091092A1/ru
Priority to US16/352,578 priority patent/US11260079B2/en
Publication of WO2019113375A2 publication Critical patent/WO2019113375A2/fr
Publication of WO2019113375A3 publication Critical patent/WO2019113375A3/fr
Anticipated expiration legal-status Critical
Priority to CONC2020/0007275A priority patent/CO2020007275A2/es
Priority to JP2023188499A priority patent/JP2024023226A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)

Abstract

L'invention concerne des compositions et des procédés utiles pour mobiliser des populations de cellules souches et progénitrices hématopoïétiques chez un donneur, ainsi que pour déterminer si les échantillons de cellules mobilisées sont appropriés à une libération pour une expansion ex vivo et/ou une utilisation thérapeutique. Grâce aux compositions et aux procédés l'invention, des cellules souches et progénitrices hématopoïétiques mobilisées peuvent être prélevées sur un donneur et administrées à un patient pour le traitement de divers troubles des cellules souches, notamment des maladies hématopoïétiques, des troubles métaboliques, des cancers et des maladies auto-immunes, entre autres. Dans certains modes de réalisation, les compositions et les procédés décrits ici permettent la mobilisation d'une population de cellules CD34dim qui ont des effets immunosuppresseurs et qui peuvent réduire l'incidence de la maladie du greffon contre l'hôte.
PCT/US2018/064335 2017-12-06 2018-12-06 Régimes posologiques pour la mobilisation de cellules souches et progénitrices hématopoïétiques Ceased WO2019113375A2 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
BR112020011186-4A BR112020011186A2 (pt) 2017-12-06 2018-12-06 regimes de dosagem para a mobilização de células-tronco e progenitoras hematopoiéticas
JP2020531468A JP2021505172A (ja) 2017-12-06 2018-12-06 造血幹細胞及び前駆細胞を動員させるための投薬レジメン
SG11202004913TA SG11202004913TA (en) 2017-12-06 2018-12-06 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
EP18829615.6A EP3720494A2 (fr) 2017-12-06 2018-12-06 Régimes posologiques pour la mobilisation de cellules souches et progénitrices hématopoïétiques
AU2018378804A AU2018378804B2 (en) 2017-12-06 2018-12-06 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CA3083783A CA3083783A1 (fr) 2017-12-06 2018-12-06 Regimes posologiques pour la mobilisation de cellules souches et progenitrices hematopoietiques
IL275077A IL275077B2 (en) 2017-12-06 2018-12-06 Dosing regimens for mobilization of hematopoietic stem and progenitor cells.
CN201880088815.6A CN111712262A (zh) 2017-12-06 2018-12-06 用于动员造血干细胞和祖细胞的给药方案
MX2020005878A MX2020005878A (es) 2017-12-06 2018-12-06 Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas.
IL315735A IL315735A (en) 2017-12-06 2018-12-06 Dosing Regimens for the Mobilization of Hematopoietic Stem and Progenitor Cells
EA202091092A EA202091092A1 (ru) 2018-11-30 2018-12-06 Схема дозированного введения для мобилизации гемопоэтических стволовых клеток и клеток-предшественников
KR1020207019222A KR20200096942A (ko) 2017-12-06 2018-12-06 조혈 줄기 및 자손 세포의 동원을 위한 투여 요법
US16/352,578 US11260079B2 (en) 2017-12-06 2019-03-13 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CONC2020/0007275A CO2020007275A2 (es) 2017-12-06 2020-06-16 Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas
JP2023188499A JP2024023226A (ja) 2017-12-06 2023-11-02 造血幹細胞及び前駆細胞を動員させるための投薬レジメン

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US15/834,017 US10058573B1 (en) 2017-12-06 2017-12-06 Dosing regimens for the mobilization of hematopoietic stem cells
US15/834,017 2017-12-06
US201762596056P 2017-12-07 2017-12-07
US62/596,056 2017-12-07
US16/101,676 2018-08-13
US16/101,676 US20190167726A1 (en) 2017-12-06 2018-08-13 Dosing Regimens for the Mobilization of Hematopoietic Stem Cells
US201862753656P 2018-10-31 2018-10-31
US62/753,656 2018-10-31
US201862773954P 2018-11-30 2018-11-30
US62/773,954 2018-11-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16/101,676 Continuation-In-Part US20190167726A1 (en) 2017-12-06 2018-08-13 Dosing Regimens for the Mobilization of Hematopoietic Stem Cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/352,578 Continuation US11260079B2 (en) 2017-12-06 2019-03-13 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells

Publications (2)

Publication Number Publication Date
WO2019113375A2 WO2019113375A2 (fr) 2019-06-13
WO2019113375A3 true WO2019113375A3 (fr) 2019-07-18

Family

ID=66749948

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/064335 Ceased WO2019113375A2 (fr) 2017-12-06 2018-12-06 Régimes posologiques pour la mobilisation de cellules souches et progénitrices hématopoïétiques

Country Status (12)

Country Link
EP (1) EP3720494A2 (fr)
JP (2) JP2021505172A (fr)
KR (1) KR20200096942A (fr)
CN (1) CN111712262A (fr)
AU (1) AU2018378804B2 (fr)
BR (1) BR112020011186A2 (fr)
CA (1) CA3083783A1 (fr)
CO (1) CO2020007275A2 (fr)
IL (2) IL275077B2 (fr)
MX (2) MX2020005878A (fr)
SG (1) SG11202004913TA (fr)
WO (1) WO2019113375A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
WO2021087406A1 (fr) * 2019-11-01 2021-05-06 Magenta Therapeutics, Inc. Schémas posologiques pour la mobilisation de cellules souches et progénitrices hématopoïétiques
MX2022013493A (es) * 2020-04-27 2023-02-22 Magenta Therapeutics Inc Metodos y composiciones para transducir celulas madre y progenitoras hematopoyeticas in vivo.
EP4308694A1 (fr) * 2021-03-16 2024-01-24 Magenta Therapeutics, Inc. Schémas posologiques pour la mobilisation des cellules souches hématopoïétiques en vue d'une greffe de cellules souches chez les patients atteints de myélome multiple
CA3258771A1 (fr) * 2022-06-10 2023-12-14 Gpcr Therapeutics, Inc. Inhibiteurs de gpcr et leurs utilisations

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000333A1 (fr) * 2003-06-05 2005-01-06 Anormed Inc. Procedes de mobilisation de cellules progenitrices/souches
US20060035829A1 (en) * 2004-08-13 2006-02-16 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
WO2007047882A2 (fr) * 2005-10-18 2007-04-26 Caritas St. Elizabeth Medical Center Of Boston, Inc. Combinaison d'un antagoniste cxcr4 et d'un morphogene pour l'accroissement de l'angiogenese
WO2008017025A2 (fr) * 2006-08-02 2008-02-07 Genzyme Corporation Thérapie combinée
WO2008019371A1 (fr) * 2006-08-07 2008-02-14 Genzyme Corporation Thérapie combinée
WO2017147610A1 (fr) * 2016-02-26 2017-08-31 President And Fellows Of Harvard College Cellules souches hématopoïétiques à haut potentiel de prise de greffe
US10058573B1 (en) * 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5233044A (en) 1989-06-08 1993-08-03 Millipore Corporation Active esters for solid phase peptide synthesis
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
US6447766B1 (en) 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
ES2210255T3 (es) 1993-06-08 2004-07-01 Smithkline Beecham Corporation Metodos para mejorar la actividad biologica de quimiocinas.
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
EP0822830B1 (fr) 1995-04-27 2008-04-02 Amgen Fremont Inc. Anticorps anti-IL-8 dérivés de xenosouris immunisées
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6028172A (en) 1997-02-11 2000-02-22 Mallinckrodt Inc. Reactor and method for solid phase peptide synthesis
EP2308996A1 (fr) 1998-03-30 2011-04-13 NorthWest Biotherapeutics, Inc. Applications therapeutiques et diagnostiques basées sur le role des gêne cxcr-4 et SDF-1 dans l'oncogénèse
AP1654A (en) 1999-03-24 2006-09-01 Anormed Inc Chemokine receptor binding heterocyclic compounds.
WO2001044229A1 (fr) 1999-12-17 2001-06-21 Anormed Inc. Recepteur de chemokine liant des composes heterocycliques
DE60103052T2 (de) 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
CA2412436C (fr) 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification et utilisation des cellules progenitrices endotheliales derivees de la moelle osseuse, destinees a ameliorer la fonction du myocarde apres un accident ischemique
JP5137288B2 (ja) * 2001-07-31 2013-02-06 アノーメッド インコーポレイティド 前駆／幹細胞を動員する方法
DE60236520D1 (de) 2001-08-16 2010-07-08 Univ Pennsylvania Synthese und verwendung von reagenzien für die verbesserte dna-lipofektion und/oder prodrug- und arzneimitteltherapien mit langsamer freisetzung
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
EP2530157B1 (fr) 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Composés oligomères et compositions à utiliser dans la modulation de miARNs
KR20080025172A (ko) 2005-06-24 2008-03-19 리전츠 오브 더 유니버스티 오브 미네소타 돼지에서 인간으로의 레트로엘리먼트 전달을 감소시키기위한 사이토신 탈아미노효소의 사용
EP2650366B1 (fr) 2005-10-18 2017-03-22 Precision Biosciences Meganucleases concues rationnellement possedant une specificité sequence modifiée et une affinité de liaison pour l'ADN
EP1995316A1 (fr) 2007-05-25 2008-11-26 Qiagen GmbH Procédé de purification de cellules préservant lesdites cellules, obtention de cellules et transfection de cellules
EP2009095A1 (fr) 2007-06-28 2008-12-31 Innovalor AG Procédé de génération de céllules sensibles au glucose
EP2215223B1 (fr) 2007-10-31 2013-05-01 Precision Biosciences, Inc. Méganucléases monocaténaires conçues rationnellement contenant des séquences de reconnaissance non palindromiques
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
EP2270025A1 (fr) 2009-06-29 2011-01-05 Centre National pour la Recherche Scientifique (CNRS) Synthèse de peptide en phase solide d'alcools peptidiques
BR112012020257A8 (pt) 2010-02-11 2018-02-14 Recombinetics Inc métodos e aparelhos para produzir artiodátilos transgênicos
BR112013021785A8 (pt) 2011-02-25 2018-07-03 Recombinetics Inc animais geneticamente modificados e métodos para fazer os mesmos
US9388212B2 (en) 2013-02-21 2016-07-12 Chemical & Biopharmaceutical Laboratories Of Patras S.A. Solid phase peptide synthesis via side chain attachment
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP2946008A4 (fr) * 2013-01-15 2016-07-20 Ohio State Innovation Foundation Méthodes de mobilisation de cellules souches hématopoïétiques
KR20160023638A (ko) * 2013-02-28 2016-03-03 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 줄기세포를 이동하기 위한 방법 및 조성물
US9169287B2 (en) 2013-03-15 2015-10-27 Massachusetts Institute Of Technology Solid phase peptide synthesis processes and associated systems
WO2018085574A2 (fr) * 2016-11-02 2018-05-11 Washington University Compositions comprenant un inhibiteur d'intégrine et des agents qui interagissent avec une chimiokine et leurs procédés d'utilisation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000333A1 (fr) * 2003-06-05 2005-01-06 Anormed Inc. Procedes de mobilisation de cellules progenitrices/souches
US20060035829A1 (en) * 2004-08-13 2006-02-16 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
WO2007047882A2 (fr) * 2005-10-18 2007-04-26 Caritas St. Elizabeth Medical Center Of Boston, Inc. Combinaison d'un antagoniste cxcr4 et d'un morphogene pour l'accroissement de l'angiogenese
WO2008017025A2 (fr) * 2006-08-02 2008-02-07 Genzyme Corporation Thérapie combinée
WO2008019371A1 (fr) * 2006-08-07 2008-02-14 Genzyme Corporation Thérapie combinée
WO2017147610A1 (fr) * 2016-02-26 2017-08-31 President And Fellows Of Harvard College Cellules souches hématopoïétiques à haut potentiel de prise de greffe
US10058573B1 (en) * 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FALAHEE PATRICK C ET AL: "The Combination of GRObeta and AMD3100 Leads to Rapid and Robust Mobilization of Hematopoietic Stem Cells in Nonhuman Primates", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 130, no. Suppl. 1, 7 December 2017 (2017-12-07), pages 1920, XP009512209, ISSN: 0006-4971 *
HOGGATT JONATHAN ET AL: "Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell", CELL,, vol. 172, no. 1, 7 December 2017 (2017-12-07), pages 191, XP085336458, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2017.11.003 *
LOUIS M. PELUS: "Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand", PMC ( NIH PUBLIC ACCESS AUTHOR MANUSCRIPT), 13 January 2010 (2010-01-13), pages 1 - 16, XP055506996 *
PELUS LOUIS M ET AL: "The Combination of AMD3100 Plus GRObeta Rapidly Mobilizes Hematopoietic Stem Cells with Enhanced Homing, Adhesion and Survival Properties", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 112, no. 11, 31 October 2008 (2008-10-31), pages 71, XP009512206, ISSN: 0006-4971 *
PELUS LOUIS M ET AL: "The CXCR4 antagonist AMD3100 and the CXCR2 agonist GRO beta synergistically mobilize hematopoetic stem cells (HSC) with short and long term repopulating activity", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 108, no. 11, Part 1, 1 November 2006 (2006-11-01), pages 105A, XP002593607, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
AU2018378804A1 (en) 2020-06-11
KR20200096942A (ko) 2020-08-14
JP2021505172A (ja) 2021-02-18
EP3720494A2 (fr) 2020-10-14
WO2019113375A2 (fr) 2019-06-13
JP2024023226A (ja) 2024-02-21
MX2024004652A (es) 2024-05-07
CO2020007275A2 (es) 2020-07-31
IL275077B1 (en) 2024-10-01
BR112020011186A2 (pt) 2020-11-17
AU2018378804B2 (en) 2025-10-02
CA3083783A1 (fr) 2019-06-13
IL315735A (en) 2024-11-01
MX2020005878A (es) 2020-10-07
IL275077A (en) 2020-07-30
IL275077B2 (en) 2025-02-01
SG11202004913TA (en) 2020-06-29
CN111712262A (zh) 2020-09-25

Similar Documents

Publication Publication Date Title
PH12021550307A1 (en) T Cell Receptor Constructs And Uses Thereof
MX2024004652A (es) Pautas posologicas para la movilizacion de celulas madre y progenitoras hematopoyeticas.
MX2021000607A (es) Células t con receptor de antígeno quimérico derivadas de células madre pluripotentes inmunomodificadas.
SG10201808258SA (en) Improved methods for manufacturing adoptive cell therapies
CL2019003390A1 (es) Proteínas de anticuerpo injertadas con citocina y métodos de uso en el tratamiento del cáncer
SG10201804330YA (en) Engineered high-affinity human t cell receptors
CY1123343T1 (el) Παραγωγη μιας τραπεζας μεσεγχυματικων στρωματικων κυτταρων απο τα ομαδοποιημενα μονοπυρηνα κυτταρα πολλαπλων δοτων μυελου των οστων
EA202091333A1 (ru) Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
NZ781538A (en) Amatoxin antibody-drug conjugates and uses thereof
BR112018076306A2 (pt) composições e métodos para a supressão de células cd117+
JP2017524031A5 (fr)
MX2015006268A (es) Diferenciacion de las celulas de fibroblastos humanos.
ECSP20000655A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
CL2020003319A1 (es) Receptores del factor de crecimiento quiméricos
MX2019007890A (es) Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
WO2019217646A8 (fr) Monocytes traités par exosomes de cellules stromales mésenchymateuses et leurs utilisations
WO2014134084A3 (fr) Compositions de phf20 et jmjd3 et méthodes d'utilisation pour l'immunothérapie anticancéreuse
MY204419A (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
WO2012095743A3 (fr) Méthodes et compositions destinés à être utilisés dans des thérapies cellulaires intralymphatiques
MX2018012945A (es) Composiciones farmacéuticas y regímenes de dosificación para uso clínico de anticuerpos del antigeno 2 de las células dendríticas de la sangre.
AR108552A1 (es) Materiales y métodos para determinar los regímenes óptimos de administración para agentes terapéuticos
EP3826624A4 (fr) Utilisation d'un conjugué médicament anticorps anti-cd2 (adc) dans une thérapie cellulaire allogénique
MX2021012041A (es) Metodos para promover la diferenciacion de celulas epiteliales timicas y progenitores de celulas epiteliales timicas de celulas madre pluripotentes, celulas resultantes y usos de estas.

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3083783

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020531468

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018378804

Country of ref document: AU

Date of ref document: 20181206

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: NC2020/0007275

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 20207019222

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018829615

Country of ref document: EP

Effective date: 20200706

WWP Wipo information: published in national office

Ref document number: NC2020/0007275

Country of ref document: CO

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18829615

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020011186

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112020011186

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200603

WWR Wipo information: refused in national office

Ref document number: 1020207019222

Country of ref document: KR

WWC Wipo information: continuation of processing after refusal or withdrawal

Ref document number: 1020207019222

Country of ref document: KR